THY1 and non-small cell lung carcinoma: Moving forward, preclinical validation in intact organisms with a competent immune system will be required to determine whether there is a causal link between targeting features of peritumoral CD90+CD73+ cells and enhanced host antitumor immunity and response to ICB in NSCLC.17